2020
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Herbst R, Tsuboi M, John T, Grohé C, Majem M, Goldman J, Kim S, Marmol D, Rukazenkov Y, Wu Y. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. Journal Of Clinical Oncology 2020, 38: lba5-lba5. DOI: 10.1200/jco.2020.38.18_suppl.lba5.Peer-Reviewed Original ResearchDisease-free survivalComplete tumor resectionDFS hazard ratioAdjuvant chemotherapyData cutoffHazard ratioOverall survivalTumor resectionAdjuvant osimertinibDFS ratesEGFRm NSCLCEGFR-TKISafety profileEGFR mutation-positive NSCLCEffective new treatment strategyResected stage IISafety of osimertinibEarly-stage diseaseMutation-positive NSCLCNew treatment strategiesUnplanned interim analysisEligible ptsIIIA NSCLCNSCLC presentPS 0/1
2019
1450P Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection
Tsuboi M, Herbst R, John T, Grohe C, Majem M, Goldman J, Kim S, Yu C, Miziara J, Novello S, Urban D, Akewanlop C, Öztürk A, Quang B, Kowalski D, Marmol D, Marotti M, Laus G, Wu Y. 1450P Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection. Annals Of Oncology 2019, 30: v589. DOI: 10.1093/annonc/mdz258.010.Peer-Reviewed Original ResearchNon-small cell lung cancerBristol-Myers SquibbComplete tumor resectionEGFR mutationsBoehringer IngelheimMerck SharpAdjuvant therapyComplete resectionTumor resectionStage IB-IIIA non-small cell lung cancerEGFRm non-small cell lung cancerMutation-positive non-small cell lung cancerEarly-stage non-small cell lung cancerEGFR mutation-positive non-small cell lung cancerEli LillyOral EGFR tyrosine kinase inhibitorPositive non-small cell lung cancerT790MEpidermal growth factor receptor (EGFR) mutationsEGFR T790M mutationEGFR tyrosine kinase inhibitorsGenentech/RocheNon-squamous histologySafety of osimertinibPlacebo-controlled study
2017
P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection
Herbst R, Wu Y, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. P2.04-006 ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection. Journal Of Thoracic Oncology 2017, 12: s2399-s2400. DOI: 10.1016/j.jtho.2017.11.019.Peer-Reviewed Original ResearchRandomized studyTumor resection